Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease

Many humanized antibodies and fusion proteins targeting T-cell co-stimulatory molecules are now in late-stage clinical development (phase II, phase III) or have recently completed phase III clinical trials. Both Amevive, an LFA-3–Ig fusion protein targeting CD2, and Xanelim, a humanized anti-CD11a a...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Immunology 2001-12, Vol.13 (6), p.683-686
Main Authors: Aruffo, Alejandro, Hollenbaugh, Diane
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Autoimmune Diseases - drug therapy
Autoimmune Diseases - immunology
Autoimmune Diseases - therapy
autoimmunity
CD11a antigen
CD2
CD2 antigen
CD2 Antigens - metabolism
CD28
CD28 Antigens - metabolism
Clinical Trials as Topic
co-stimulation
Forecasting
Humans
immunotherapy
Integrin alpha4beta1
Integrins - immunology
LFA-1
LFA-3 antigen
Lymphocyte Activation
Lymphocyte Function-Associated Antigen-1 - immunology
Receptors, Lymphocyte Homing - immunology
Recombinant Fusion Proteins - therapeutic use
T-Lymphocytes - immunology
VLA-4
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many humanized antibodies and fusion proteins targeting T-cell co-stimulatory molecules are now in late-stage clinical development (phase II, phase III) or have recently completed phase III clinical trials. Both Amevive, an LFA-3–Ig fusion protein targeting CD2, and Xanelim, a humanized anti-CD11a antibody, have shown efficacy in pivotal phase III trials in patients with plaque psoriasis. These new medicines are poised to enter clinical use in 2002. Years of study of co-stimulatory molecules have yielded several drugs that have proven clinically efficacious; many other candidate drugs are in the pipeline.
ISSN:0952-7915
1879-0372
DOI:10.1016/S0952-7915(01)00279-5